Docoh
Loading...

37 results

Filter options loading...
Top filers
Top filing types
Recent filing years
FWP
PRPO Precipio Inc
31 Jul 17
Free writing prospectus
8:00pm
: Precipio, Inc. Symbol: NASDAQ: PRPO Target Offering: $8.0M Common Stock and Warrants Use of Proceeds: Growth capital, R&D Target Pricing: August 2017 … R&D – 15 years in laboratory product development and assay design, deep understanding of molecular and genetic biology. SCIENTIFIC ADVISORY Jeffrey
FWP
PRPO Precipio Inc
1 Aug 17
Free writing prospectus
8:00pm
Growth Capital, R&D Sole Book-Runner Aegis Capital Corp. Target Pricing Week of August 7th, 2017 Executive summary OVERVIEW THE VISION Eradicate … spanning all fields of reference laboratory operations. Ayman Mohamed, VP R&D – 15 years in laboratory product development and assay design, deep
8-K
EX-99.1
PRPO Precipio Inc
18 Nov 03
Other events
7:00pm
to commercialize nucleic acid-based therapeutic and diagnostic products a comprehensive menu of services, including nucleic acid chemistry R&D, process … , "There is currently a limited pool of industry expertise to take oligonucleotide pharmaceuticals rapidly from R&D into the clinic. With Transgenomic
8-K
EX-99.1
PRPO Precipio Inc
13 Jan 15
Regulation FD Disclosure
7:00pm
offerings allowing broad and rapid adoption Biomarker Services for Pharma and Biotech R&D to identify and detect biomarkers (Mutations) in tissue, blood … use MX ICP products & technologies on global basis Reagent kits for R&D and clinical use to enable detection of mutations on any platform in any lab 15
8-K
EX-99.1
PRPO Precipio Inc
10 Dec 14
Regulation FD Disclosure
7:00pm
Licenses Kits Services for Pharma and Biotech R&D to identify and detect biomarkers (Mutations) in tissue and blood samples Licensing agreements … patient outcomes Reagent kits for R&D and Clinical use to enable detection of known and unknown mutations on any platform by any lab globally 22
8-K
EX-99.1
nf57lhulo9db
12 Nov 17
Precipio, Inc. Announces Closing of $2,748,000 Registered Direct Offering
7:00pm
8-K
EX-99.1
p1gigpcbac1e6xomrl
27 Apr 04
Other events
8:00pm
8-K
EX-99.1
iw3ebgevw695ta bwp
16 Oct 18
Precipio Announces Third Quarter 2018 Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues
4:41pm
8-K
EX-99.1
kyw2d94s4zs1zbcie
11 Jul 06
Departure of Directors or Principal Officers
8:00pm
8-K
EX-99.1
wytt3mb5e
28 Mar 04
Other events
7:00pm
8-K
EX-99.1
blmm5io2vncsy5
29 Jun 17
Precipio Diagnostics and Transgenomic Complete Merger
8:00pm
8-K
EX-99.1
w82hfgu4h8bfu2 w5
21 Mar 04
Other events
7:00pm
8-K
EX-99.1
0r7 5kgfln
7 Sep 17
Precipio Provides Shareholder Update Letter
8:00pm
8-K
EX-99.1
4i541567 btl
8 Jun 15
Departure of Directors or Certain Officers
8:00pm
8-K
EX-99.1
65t0zhm
13 Nov 17
Precipio Appoints Samuel D. Riccitelli as Chairman of the Board of Directors and Elects David Cohen as Director
7:00pm
8-K
EX-99.1
hp5lpr2wfh530y tei
12 Aug 04
Results of Operations and Financial Condition
8:00pm
8-K
EX-99.1
fk1g0j
20 Nov 17
Precipio Announces Third Quarter 2017 Financial Results and Provides Corporate Update
7:00pm
8-K
hj5ijb8
9 Aug 18
Precipio Appoints New Board Member to Replace Departing Director
4:31pm
10-K/A
isblgj
20 Aug 15
Annual report (amended)
8:00pm
10-Q
0ohnwa jsilo7tyfj9a
14 May 21
Quarterly report
4:01pm